Selumetinib (Koselugo) Application Guide and Medication Instructions

Selumetinib, known as Koselugo orKoselugo, is a cutting-edge drug developed by AstraZeneca. Its core active ingredient is selumetinib. As a specific inhibitor of mitogen-activated protein kinase kinase 1 and 2 (MEK1/2), it plays a vital role in cell signal transduction pathways. The drug mainly targets the RAF-MEK-ERK pathway regulated by RAS. This pathway is often abnormally activated in a variety of cancers and is a key driver of cancer progression.

Selumetinib is a specialty prescription drug designed for use in pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) and symptomatic, inoperable plexiform neurofibromas (PN). The establishment of this precise indication marks a new treatment option for these patients who have long faced treatment challenges.

In terms of medication regimen, the recommended dosage of selumetinib is to be taken twice daily, with each dose being 25 mg/m2, and should be taken orally on an empty stomach (a fasting time of at least 2 hours and 1 hour before and after taking the drug, respectively). For patients with moderately impaired liver function, the dose needs to be adjusted to 20 mg/m², and the frequency of taking the drug twice a day is also maintained.

It is particularly noteworthy that selumetinib must be swallowed intact and the capsule shell is strictly prohibited from crushing, chewing, breaking or opening. Therefore, before initiating treatment, the patient's swallowing ability needs to be fully assessed, and the use of this product should be avoided in patients who are unable or unwilling to swallow the whole tablet. If the patient experiences vomiting within a short period of time after taking the medication, it is not recommended to take another dose. Instead, the patient should wait until the next prescribed medication time before continuing to take the medication.

At present, selumetinib has been officially launched in the Chinese market. For specific price information, please consult the local medical institution pharmacy. In addition, the Lao market also provides more affordable generic versions, but please be sure to purchase through formal channels to ensure the legality of the source of the medicine and the reliability of the quality.

In summary, selumetinib, as an innovative therapy, provides a new treatment option for patients with neurofibromatosis type 1. During the medication process, patients should strictly abide by the doctor's instructions to ensure the accuracy and safety of medication in order to obtain the best therapeutic effect.

References:

https://www.nicerx.com/medications/